TO STUDY THE TREATMENT FREE REMISSION RATE AND THE FACTORS ASSOCIATED WITH IT IN PATIENTS WITH CML WHO ARE ON GENERIC FORMS OF IMATINIB

PGIMER CHANDIGARH0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients diagnosed with CML-CP who are receiving treatment with Imatinib for at least 3 years of duration and are > 18 years old.
•2.The patients must have attained the milestones of disease monitoring as per the recommended guidelines.
•3.The patients must be compliant to the treatment with regular follow up and molecular monitoring. (As per data recorded in their respective files)
•4.The patients must have molecular response of at least MR 4 (BCR-ABL transcript levels < 0.01), which is sustained for at least 3 years before the imatinib discontinuation is attempted.
•5.Patients who are on generic forms of imatinib will be included in the study.
•6.Before entering the study the patients should understand the investigational nature of this study, regular follow up as advised and should sign the consent form.

•1.Patients diagnosed with advanced form of disease CML-AP (Accelerated Phase) and CML-BP (Blast Phase).
•2.Patients who are incompliant to the treatment with frequent interruption of medication despite being in sustained molecular response.
•3.Patients who are seropositive for HIV, HBsAg and HCV.
•4.Patients who have other concomitant disease (connective tissue disorders, second malignancy etc.) will be excluded from the study.
•5.Those who do not sign the consent form.

发起方